Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132829 | 0.93 | HPRT1 (0.42) | TDP1HPRT1L3MBTL1LMNAMMP8 | |
| SCHEMBL20132791 | 0.93 | HPRT1 (0.42) | TDP1HPRT1L3MBTL1LMNAMMP8 | |
| SCHEMBL16774770 | 0.80 | NPC1 (0.44) | TSHRNPC1SMN1; SMN2LTA4H | |
| SCHEMBL16774864 | 0.80 | NPC1 (0.44) | TSHRNPC1SMN1; SMN2LTA4H | |
| SCHEMBL5321935 | 0.79 | TDP1 (0.67) | TDP1MMP1MMP3L3MBTL1TSHR | |
| SCHEMBL20128498 | 0.79 | NPC1 (0.43) | NPC1SMN1; SMN2LTA4H | |
| SCHEMBL20128492 | 0.79 | NPC1 (0.43) | NPC1SMN1; SMN2LTA4H | |
| SCHEMBL7429704 | 0.78 | TDP1 (0.61) | TDP1MMP1MMP3L3MBTL1TSHR | |
| SCHEMBL27707724 | 0.77 | L3MBTL1 (0.52) | TDP1L3MBTL1TSHRLMNAMMP8 | |
| SCHEMBL5857539 | 0.76 | TDP1 (0.61) | TDP1MMP1MMP3L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | TDP1 2369/4885HPRT1 2055/4885MMP1 1396/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | TDP1 2369/4885HPRT1 2055/4885MMP1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.